非瓣膜性心房颤动住院患者使用利伐沙班合理性评价  

Rationality analysis of rivaroxaban in inpatients with nonvalvular artial fibrillation

作　　者：黄溯源 梁婷 吴建博 龚皓鸣 沈杰 宋钟娟 HUANG Su-yuan;LIANG Ting;WU Jian-bo;GONG Hao-ming;SHEN Jie;SONG Zhong-juan(Department of Pharmacy,Huadong Hospital Affiliated to Fudan University,SHANGHAI 200040,China)

机构地区：[1]复旦大学附属华东医院药剂科

出　　处：《中国新药与临床杂志》2019年第11期699-702,共4页Chinese Journal of New Drugs and Clinical Remedies

基　　金：上海医院药学科研基金(2015-YY-01-04)

摘　　要：目的分析非瓣膜性心房颤动住院患者使用利伐沙班的合理性及安全性。方法采用回顾性调查方法,参照药品说明书等标准评价使用利伐沙班的非瓣膜性心房颤动住院患者的用药指征、用法用量、药物相互作用及安全性,并考察相关因素对服用利伐沙班后出血的影响。结果共纳入122例患者,利伐沙班用药指征符合率为100%,但利伐沙班日剂量与指南推荐相符率仅为9.8%。服用利伐沙班后出血发生率为9.8%,年龄(≥75岁)及联合使用非甾体抗炎药的患者更易发生出血(OR分别为0.162和0.175)。结论本院非瓣膜性心房颤动住院患者的利伐沙班使用尚合理,但量效关系尚需进一步临床验证。AIM To analyze the rationality and safety of rivaroxaban in inpatients with nonvalvular atrial fibrillation( NAF). METHODS The retrospective investigation method was used to evaluate the indications,dosage and administration, drug interaction and safety of NAF inpatients treated with rivaroxaban according to drug specifications and other criteria. The factors associated with the hemorrhage after using rivaroxaban were investigated. RESULTS A total of 122 patients were enrolled. The coincidence rate of indication of rivaroxaban was 100%, but only 9.8% patients took the right dosage in daily according to the criteria. The incidence of bleeding was 9.8%. The logistic regression showed that patients with rivaroxaban have risks of bleeding when they were age over 75 and combining with non-steroidal anti-inflammatory drugs( OR = 0.162 and 0.175,respectively). CONCLUSION The use of rivaroxaban in inpatients with NAF in our hospital is reasonable, but the dose-effect relationship needs further clinical verification.

关 键 词：利伐沙班 心房颤动 抗凝药 住院病人 合理用药 

分 类 号：R973.2[医药卫生—药品]